18 June, 2026
The global landscape of medical publishing witnessed a significant milestone today with the release of the 2026 Journal Citation Reports (JCR) by Clarivate. For the European Respiratory Society (ERS), the data confirms a banner year, cementing the organization’s position as a premier publisher in the field of respiratory medicine. As the scientific community continues to grapple with complex pulmonary challenges—ranging from the lingering effects of global pandemics to the rising incidence of chronic respiratory diseases—the impact factors (IF) assigned to the ERS journal portfolio serve as a critical benchmark for clinical relevance, research quality, and academic influence.
The Main Facts: A Banner Year for ERS Publications
The 2026 JCR data highlights a remarkable performance across the ERS publishing stable. Leading the charge is the European Respiratory Journal (ERJ), which has secured the number two spot in the highly competitive Respiratory System category. With an impressive Impact Factor of 23.8, the ERJ remains the flagship publication for the society, attracting the most high-stakes, transformative research in the field.
However, the success was not limited to the flagship title. The entire portfolio saw a strategic upward trajectory:
- European Respiratory Review reached an Impact Factor of 10.8, reflecting its status as a vital source for clinical updates and comprehensive reviews.
- ERJ Open Research climbed to an Impact Factor of 4.4, underscoring the growing importance of open-access pathways in disseminating rapid, transparent scientific findings.
- Breathe achieved an Impact Factor of 4.5, reinforcing its role as an essential educational resource for respiratory professionals globally.
These figures represent more than just statistics; they reflect the cumulative effort of thousands of researchers, clinicians, and editorial staff dedicated to advancing the standard of care for patients with lung disease.
A Chronology of Academic Influence
To understand the weight of the 2026 rankings, one must view the ERS publishing trajectory through a historical lens. The journey of the European Respiratory Journal from a specialized European publication to a global powerhouse has been a decades-long endeavor.
The Foundation (1990s–2010s)
In the early years, the ERJ established itself as a rigorous peer-review journal. As digital dissemination became the norm in the early 2000s, the society invested heavily in infrastructure to ensure that European respiratory science was accessible to the burgeoning markets in Asia, North America, and beyond.
The Expansion Era (2015–2022)
Recognizing that the field of respiratory medicine was diversifying, the ERS expanded its portfolio. The launch of ERJ Open Research provided a platform for researchers looking to share data without the barriers of traditional subscription models. Simultaneously, the evolution of Breathe into a highly cited educational journal provided a bridge between bench science and bedside practice.
The Current Milestone (2023–2026)
The period leading up to the 2026 JCR release was marked by a shift in editorial strategy. By prioritizing rapid publication and rigorous statistical review, the ERS journals were able to capture the most influential studies in the post-pandemic era. The consistent year-on-year growth culminating in the 2026 figures serves as a testament to the stability and prestige of the ERS brand.
Supporting Data: Understanding the Impact Factor
In the ecosystem of academic publishing, the Impact Factor remains the most widely recognized—if occasionally debated—metric for evaluating the quality of a journal. It is calculated by dividing the number of citations in a given year by the total number of articles published in the two preceding years.
For the ERS, the data indicates a high "citation density." This means that the articles published in ERJ, European Respiratory Review, ERJ Open Research, and Breathe are not merely being read; they are being utilized as foundational building blocks for subsequent research.
Category Benchmarking
Within the Respiratory System category, the competition is fierce. With top-tier journals vying for the most groundbreaking clinical trials and molecular discoveries, maintaining a spot in the top three is an indicator of exceptional editorial curation. The ERJ’s 23.8 IF confirms that it is the primary venue where the global community looks for consensus statements, new treatment guidelines, and high-impact clinical trials.
The Role of Open Access
The growth of ERJ Open Research to 4.4 is particularly telling. In the current publishing climate, researchers are increasingly incentivized to choose open-access journals to maximize the visibility and societal impact of their work. The ERS’s commitment to supporting this model while maintaining the prestige of its subscription-based counterparts has allowed the society to capture a wider share of the global research output.
Official Responses and Editorial Philosophy
Following the announcement, ERS leadership expressed profound gratitude toward the stakeholders who made these metrics possible. The success of a journal is rarely the result of a single editorial decision; rather, it is the result of an intricate network of intellectual labor.
"We are deeply grateful to our authors, who continue to entrust us with their most innovative work," said a spokesperson for the ERS Publications Committee. "Equally, the unsung heroes of our journals—our reviewers and editors—deserve immense credit. Their dedication to the peer-review process ensures that only the highest quality, most ethically sound science makes it to publication. These rankings are a reflection of their collective commitment to scientific integrity."
The editorial philosophy at the ERS emphasizes not only the "impact" of a paper, but also its reproducibility and clinical utility. By fostering a culture where reviewers provide constructive, deep-dive feedback, the journals help authors refine their work, thereby increasing the long-term citation potential of every article published.
The Implications: What This Means for the Future of Respiratory Medicine
The 2026 JCR rankings carry significant implications for the global respiratory community, researchers, and patients alike.
For Researchers
A high impact factor acts as a beacon for top-tier talent. Researchers in early-to-mid career stages are naturally drawn to journals that guarantee high visibility for their findings. The ERS’s current standing ensures that the society will continue to attract the brightest minds in pulmonology, oncology, and critical care, creating a self-sustaining cycle of high-quality submissions.
For Clinical Practice
Impact factors often correlate with the speed at which research is integrated into clinical guidelines. When an article is published in a journal with an IF of 23.8, it is likely to be read by the policy-makers and clinical leads who draft the standards of care. Consequently, the research published in the ERJ is more likely to influence how asthma, COPD, and interstitial lung diseases are treated in hospitals worldwide.
For the Global Scientific Community
As the ERS journals continue to grow in influence, they act as a unifying force for the international respiratory community. In an era where scientific fragmentation is a risk, the ERS provides a centralized, authoritative voice that helps bridge the gap between regional clinical practices and global scientific standards.
Conclusion: Looking Ahead
The release of the 2026 Journal Citation Reports is not a final destination, but rather a checkpoint in the ongoing evolution of the European Respiratory Society’s publishing mission. While the numbers are cause for celebration, the broader mission remains the same: to improve respiratory health through the dissemination of world-class research.
As we move toward 2027, the challenge for the ERS will be to maintain this momentum in an increasingly crowded and digital-first publishing environment. With a robust portfolio that spans from fundamental bench research to practical clinical education, the society is well-positioned to remain at the forefront of respiratory science for years to come.
For those interested in contributing to this legacy, the ERS invites researchers and clinicians to submit their work to the ERS publications. Whether through the flagship European Respiratory Journal or the accessible platforms of ERJ Open Research and Breathe, the society remains committed to providing a home for the very best ideas in pulmonary medicine.
For more information on submission guidelines and to view the latest research, visit the official ERS manuscript submission portal.
